Recommendations for Prevention and Control of Influenza in Children, 2024–2025: Policy Statement

Children consistently have the highest attack rates of influenza in the community during seasonal influenza epidemics. Children, especially those younger than 5 years and those with certain underlying medical conditions, can experience substantial morbidity, including severe or fatal complications, from influenza virus infection.^1,2 A higher risk of influenza hospitalization before 5 years of age has been noted in children born preterm (<37 weeks’ gestation) or near-term (37–38 weeks’ gestation).³ School-aged children bear a large influenza disease burden and are more likely to receive influenza-related medical care compared with healthy adults.⁴ Children also play a pivotal role in the transmission of influenza virus infection to household and other close contacts.^1,5,6 Influenza vaccination of children not only reduces disease burden among children but also among household members, close contacts, and community members of all ages.^7,8 By reducing the burden of respiratory illnesses, influenza vaccination helps to preserve health care capacity, especially when other viruses are cocirculating. The American Academy of Pediatrics (AAP) recommends routine influenza vaccination and use of antiviral agents for the prevention and treatment of influenza in children, respectively. Unfortunately, influenza vaccination coverage decreased again during the 2023–2024 influenza season. Through May 11, 2024, only 53.9% of children 6 months to 17 years of age had been vaccinated, more than 8.5 percentage points lower than in May of 2020.⁹ Non-Hispanic Black children had the lowest influenza vaccine coverage (49.1%) compared with several groups with higher coverage, including non-Hispanic white children (51.1%), Hispanic children (59.6%), and children identified as other race or ethnicity (58.8%). Coverage levels were also lower among children residing in rural areas (39.9%) compared with suburban (53.7%) or urban (59.5%) areas.⁹ 

Efforts to increase influenza vaccination, including strategies to decrease disparities in vaccine access and delivery and to counter vaccine hesitancy, are urgently needed.

This policy statement summarizes updates and recommendations for the 2024–2025 influenza season. An accompanying technical report provides further detail regarding recent influenza seasons, influenza vaccine effectiveness, detailed discussion of inactivated (nonlive) and live attenuated influenza vaccines, vaccine storage, vaccination coverage, timing of vaccination, duration of protection, and vaccine delivery strategies.¹⁰ 

1. All licensed vaccines available in the United States this season are trivalent.

2. The compositions of influenza vaccines for the 2024–2025 season have been updated (Table 1).

   • The recommended influenza A (H1N1) pdm09 and influenza B Victoria lineage components of the vaccine are unchanged for this season.^11,12 

   • The influenza A (H3N2) component is new this season.

   • Influenza B Yamagata lineage virus has not circulated since 2020, and this component has been removed from seasonal influenza vaccines in the United States.

3. Coadministration with other recommended immunizations, including nirsevimab, is emphasized.

4. Recommendations for influenza treatment and prophylaxis have been simplified.

5. Recommendations for immunization of immunocompromised hosts have been updated.

6. Recommendations for improving access to influenza vaccine are emphasized.

Children younger than 5 years, especially those younger than 2 years, and children with certain underlying medical conditions are at increased risk of hospitalization and complications attributable to influenza (Table 2).¹⁰ Although influenza vaccination is recommended for everyone starting at 6 months of age, emphasis should be placed on ensuring that children at high risk, medically vulnerable children, and children with medical complexity, as well as their parents and guardians, other household contacts, and caregivers receive annual influenza vaccine (Table 3). Additionally, increased efforts are needed to eliminate barriers to vaccination in all persons experiencing higher rates of adverse outcomes from influenza. Racial and ethnic disparities exist, resulting in severe outcomes from influenza. In one cross-sectional study spanning 10 influenza seasons, Black, Hispanic, and American Indian/Alaska Native people had higher rates of influenza-associated hospitalizations and ICU admissions, and disparities were highest in children ≤4 years of age.¹³ Influenza-associated in-hospital deaths were threefold to fourfold higher in Black, Hispanic, and Asian/Pacific Islander children compared with white children.¹³ Inequities in health care system access and other social drivers of health contribute to severe outcomes and increased mortality in these groups.

The seasonal influenza vaccines licensed for children for the 2024–2025 season are shown in Table 4. More than one product may be appropriate for a given patient, and there is no preference for one product over another. Thus, influenza vaccination should not be delayed to obtain a specific product.

All 2024–2025 seasonal influenza vaccines available in the United States are trivalent and contain hemagglutinin derived from the same influenza strains as recommended by the World Health Organization and the US Food and Drug Administration (FDA)’s Vaccines and Related Biological Products Advisory Committee for the Northern Hemisphere (Table 1).^11,12 The influenza A (H3N2) vaccine component for the 2024–2025 season is different from the previous year, whereas the influenza A (H1N1) and influenza B Victoria lineage are unchanged. Influenza B Yamagata lineage components have been removed from vaccines available in the United States. Different but antigenically related influenza A strains are included in this season’s egg-based and cell-based or recombinant vaccines. They are matched to the strains expected to circulate in the 2024–2025 season.

1. The AAP recommends influenza vaccination of everyone 6 months and older, including children and adolescents, during the 2024–2025 influenza season.

2. The AAP recommends any licensed influenza vaccine product appropriate for age and health status and does not prefer one product over another, including inactivated (nonlive) influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Recombinant influenza vaccine (RIV) is another option for persons ≥18 years of age. Physicians and other clinicians who care for children may administer whichever product is appropriate and readily available to capture all opportunities for influenza vaccination and achieve the highest possible coverage this season.

3. LAIV should not be used for immunocompromised persons and persons with some chronic medical conditions (Table 5).

4. The number of influenza vaccine doses recommended for children remains unchanged in the 2024–2025 influenza season and depends on the child’s age at first dose administration and influenza vaccination history (Fig 1). Children 6 months through 8 years of age who are receiving influenza vaccine for the first time or who received only 1 dose before July 1, 2024, or whose vaccination status is unknown should receive 2 doses of influenza vaccine at least 4 weeks apart. Doses given up to 4 days before the minimum suggested interval should be regarded as acceptable. All other children should receive 1 dose this season. For children 8 years of age who require 2 doses of influenza vaccine, both doses should be administered even if the child turns 9 years of age between dose 1 and dose 2.

5. The total number of full doses appropriate for age should be administered. If a child is inadvertently vaccinated with a formulation only approved for older children or adults, the dose should be counted as valid. If a lower dose than recommended is inadvertently administered to a child 36 months or older (eg, 0.25 mL), an additional 0.25-mL dose should be administered to provide a full dose of 0.5 mL as soon as possible. A 0.5-mL dose of any IIV should not be split into 2 separate 0.25-mL doses.

6. When a child is recommended to receive 2 doses of vaccine in a given season, the doses do not need to be the same brand. A child may receive a combination of IIV and LAIV if appropriate for age and health status.

7. Influenza vaccine should be offered to children as soon as it becomes available, especially to those recommended to receive 2 doses. The recommended dose(s) ideally should be received by the end of October for optimal protection before the influenza season begins. Most adults, particularly those ≥65 years of age and pregnant persons in the first or second trimester, should not be immunized in July and August because of a concern about waning immunity. Influenza vaccination efforts should continue throughout the season.

8. IIV (or RIV, if age-appropriate) may be administered simultaneously with or at any time before or after other inactivated (nonlive) or live vaccines or nirsevimab. LAIV may be administered simultaneously with other live or inactivated (nonlive) vaccines, including coronavirus disease 2019 (COVID-19) vaccines. If not administered simultaneously, ≥4 weeks should pass between the administration of LAIV and other nonoral live vaccines. A 4-day grace period is permitted (ie, vaccine doses administered ≤4 days before the minimum interval or age are considered valid).

1. For children with malignant neoplasms receiving chemotherapy, the optimal time to provide IIV is not well defined, but generally, vaccine should be administered ≥2 weeks before cytotoxic chemotherapy, when clinically possible.

2. For children who have received anti-B cell therapies (eg, rituximab, alemtuzumab), IIV should be deferred for 6 months after last dose, ideally once there is evidence of B cell recovery.

3. Household contacts of immunocompromised individuals should receive influenza vaccine annually.

4. Nonlive vaccines should be considered ≥6 months after CD19-targeted chimeric antigen receptor-T–cell infusion in patients who are in remission and do not require additional chemotherapy or hematopoietic cell transplantation. For children who will be starting anti-B cell therapies, IIV should optimally be provided at least 2 to 4 weeks before starting these therapies.

5. For hematopoietic cell transplant recipients, IIV can be given starting 4 to 6 months after transplantation. For solid organ transplant (SOT) recipients, IIV can be given starting 3 months after receipt of an SOT, although it may be considered ≥1 month after SOT during the influenza season.

6. Although high-dose IIV is not approved for use in children, clinicians could consider administering 2 doses of high-dose trivalent inactivated (nonlive) influenza vaccine (IIV3) 28 to 42 days apart in pediatric hematopoietic cell transplant recipients 3 to 17 years of age.^14,15 

1. Pediatricians who interact with pregnant individuals should recommend influenza vaccination, emphasizing the benefits of vaccination for them and their infants.

2. Pregnant individuals may receive IIV (or RIV if age-appropriate) at any time during pregnancy to protect themselves and their infants. Those who do not receive it during pregnancy should receive influenza vaccine before hospital discharge. Those who decline the vaccine during hospitalization should be encouraged to discuss influenza vaccination with their obstetrician, family physician, nurse midwife, or other trusted clinician.

3. Influenza vaccination is safe for the breastfeeding parent and infant.

1. Individuals traveling to the tropics, on cruise ships, or to the Southern hemisphere during April to September should consider seasonal influenza vaccination ≥2 weeks before departure if not vaccinated during the preceding fall or winter and if vaccine is available. The dating period, or expiration date, of seasonal influenza vaccines is based on stability studies conducted by each manufacturer, and no final vaccine formulations in the United States are labeled with an expiration date that extends past June 30 of the prior winter influenza season.¹⁶ 

1. The AAP supports mandatory influenza vaccination of health care personnel as a crucial strategy for reducing health care-associated influenza virus infections.

1. Efforts should be made to promote influenza vaccination of all children, especially children younger than 5 years and those in high-risk groups (Table 2) and their contacts, unless contraindicated (Table 5). To promote influenza vaccination in communities affected by health disparities, it is important to include community members in the development of culturally relevant strategies. Evidence-based strategies for increasing influenza vaccine uptake are presented in Table 3. Strategies for communicating with families about vaccines and promoting vaccine confidence are available at https://www.aap.org/vaccinecommunication.

2. Increasing access and reducing barriers to vaccination in schools, pharmacies, hospitals, and other nontraditional settings could improve vaccination rates, although vaccination in the medical home is optimal for young children to facilitate other necessary services, including well care, preventive screening, anticipatory guidance, and other important childhood vaccinations.

3. When influenza vaccination takes place in a nontraditional setting, appropriate documentation should be provided to patients and to the medical home. Settings that offer influenza vaccination should submit details about the vaccination to the state or regional immunization information systems, including all content needed to support communication of this information to the patient’s medical home.

4. Practices serving children and adolescents may consider offering influenza vaccine to family members and close contacts.¹⁷ 

1. All participants in immunization efforts should work to eliminate disparities in influenza vaccine supply between privately insured patients and those eligible for vaccination through the Vaccines for Children program.

2. Information about influenza vaccine and influenza vaccine clinics should be provided to eligible children and their families in their preferred language, especially those who may experience barriers to preventive care.

3. Public and private payers should offer adequate payment for influenza vaccine supply and administration to pediatric populations, update payments for influenza vaccine so that physicians and other clinicians who care for children are paid for administering doses in July and August, and eliminate remaining “patient responsibility” cost barriers to influenza vaccination where they still exist.

Contraindications and precautions for the use of influenza vaccines are described in Table 5, and further details are provided in the technical report.¹⁰ Key points include:

1. Product-specific contraindications must be considered when selecting the type of influenza vaccine to administer.¹⁸ 

2. Although a history of severe allergic reaction (eg, anaphylaxis) to any influenza vaccine is generally a contraindication to future receipt of influenza vaccines, children who have had a severe allergic reaction after influenza vaccination should be evaluated by an allergist to help identify the vaccine component responsible for the reaction and to determine whether future vaccine receipt is appropriate. Children who are allergic to gelatin (very rare) should receive IIV (or RIV if age-appropriate) instead of LAIV.

3. Children with egg allergy can receive any influenza vaccine without any additional precautions beyond those recommended for all vaccines.

4. Children with acute moderate or severe illness may receive influenza vaccine as soon as their acute illness has improved; strategies to promote timely receipt once recovered from illness should be employed (ie, schedule return visit; send reminder message; if hospitalized, administer before discharge from hospital setting); children with mild illness, including a low-grade fever, should still be vaccinated.

1. Influenza testing should be performed in children with signs and symptoms of influenza when test results are anticipated to impact clinical management (eg, to inform the decision to initiate antiviral or avoid antibiotic therapy, pursue other diagnostic testing, initiate infection prevention and control measures, or distinguish from other respiratory viruses with similar symptoms [eg, severe acute respiratory syndrome coronavirus 2]).

2. When influenza is circulating in the community, hospitalized patients with signs and symptoms of influenza should be tested with a molecular assay with high sensitivity and specificity (eg, reverse transcriptase-polymerase chain reaction).

3. At-home tests are available for children as young as 2 years of age, but data on the use of these tests in pediatric patients is limited. The use of at-home test results to inform treatment decisions should be informed by the sensitivity and specificity of the test, the prevalence of influenza in the community, the presence and duration of compatible signs and symptoms, and individual risk factors and comorbidities.

Antiviral medications available for the treatment and prophylaxis of influenza in children are described in Table 6. Key points include:

1. Antiviral medications are an important adjunct in the control of influenza but are not a substitute for influenza vaccination. Physicians and other clinicians who care for children should promptly identify patients suspected of having influenza for timely initiation of antiviral treatment when indicated and based on shared decision-making between the clinician and child’s parent or guardian to reduce morbidity and mortality. Potential benefits and harms of antiviral treatment are summarized in the technical report ([https://www.pediatrics.org/cgi/doi/10.1542/peds.2024-068508]; see section “Rationale for Influenza Treatment in Children”).¹⁰ 

2. The AAP considers oseltamivir the preferred antiviral medication for patients with influenza A and B because of the cumulative experience of this drug in children, relative cost, and ease of administration.

3. Although best results are observed when the child is treated within 48 hours of symptom onset, antiviral therapy should still be considered beyond 48 hours in certain cases (see below).

4. Antiviral treatment should be offered as early as possible to the following individuals, regardless of influenza vaccination status and duration of symptoms^*:

   • Any child hospitalized with suspected or confirmed influenza disease.

   • Any child with severe, complicated, or progressive influenza disease, regardless of health care setting (ie, inpatient or outpatient).

   • Any child with suspected or confirmed influenza disease of any severity if they are younger than 5 years or they belong to other high-risk groups for influenza complications, regardless of health care setting (ie, inpatient or outpatient) (Table 2).

5. Facilitate quick access to antiviral treatment near the onset of symptoms.

6. Treatment may be considered for the following individuals in the outpatient setting after discussing benefits and risks with parents or guardians:

   • Any child with suspected or confirmed influenza disease who is not at high risk for influenza complications if treatment can be initiated within 48 hours of illness onset.

   • Any child with suspected or confirmed influenza disease whose siblings or household contacts are either younger than 6 months or at high risk for influenza complications (Table 2).

7. Initiation of antiviral therapy should be based on signs and symptoms consistent with influenza infection and epidemiologic factors (eg, influenza circulating in the community, known exposure, etc). Provision of antiviral therapy does not require a positive test for influenza.

1. Chemoprophylaxis is not a substitute for vaccination, and among some high-risk people, both vaccination with IIV or RIV and antiviral chemoprophylaxis may be considered.

2. The AAP considers oseltamivir to be the preferred postexposure chemoprophylaxis for patients with influenza A and/or B.

3. Postexposure chemoprophylaxis should only be used when antiviral agents can be initiated within 48 hours of exposure.

4. Postexposure chemoprophylaxis should not be used for routine or widespread prophylaxis outside of institutional outbreaks.

   • Postexposure chemoprophylaxis is recommended for unvaccinated staff and unvaccinated children in a closed institutional setting with children at high risk for influenza complications (eg, extended-care facilities) to control influenza outbreaks.

5. Postexposure chemoprophylaxis can be considered after known or suspected influenza exposure for children in the following situations:

   • Any child at high risk for influenza complications for whom influenza vaccine is contraindicated or has not yet been administered this season.

   • Any child at high risk for influenza complications who received influenza vaccine in the past 2 weeks (ie, optimal immunity may not yet be achieved).

   • Any child at high risk for influenza complications who has been vaccinated but may not have mounted a sufficient immune response (ie, immunosuppression).

   • Any child at high risk for influenza complications when influenza virus strains circulating in the community are not well matched with those of the seasonal influenza vaccine per the Centers for Disease Control and Prevention (CDC) (https://www.cdc.gov/flu/vaccines-work/effectiveness-studies.htm).

   • Any unvaccinated child with a family members or close contact who is at high risk for influenza complications and is unable to be otherwise effectively protected from influenza.

6. Postexposure chemoprophylaxis can be considered for known or suspected influenza exposed family members or close contacts of children at high risk for influenza complication in the following situations:

   • Unvaccinated family members and close contacts who are likely to have ongoing, close exposure to unvaccinated children at high risk for influenza complications or unvaccinated children who are younger than 24 months.

   • Influenza virus strains circulating in the community are not well matched with those of the seasonal influenza vaccine per the CDC.

Sean T. O’Leary, MD, MPH, FAAP, Chairperson

James D. Campbell, MD, MS, FAAP, Vice Chairperson

Monica I. Ardura, DO, MSCS, FAAP

Kristina A. Bryant, MD, FAAP

Mary T. Caserta, MD, FAAP

Claudia Espinosa, MD, MSc, FAAP

Robert W. Frenck, Jr, MD, FAAP

C. Mary Healy, MD

Chandy C. John, MD, MS, FAAP

Athena P. Kourtis, MD, PhD, MPH

Aaron Milstone, MD, MHS, FAAP

Angela Myers, MD, MPH, FAAP

Pia Pannaraj, MD, MPH, FAAP

Adam J. Ratner, MD, MPH, FAAP

Kristina A. Bryant, MD, FAAP

Annika M. Hofstetter, MD, PhD, MPH, FAAP

Juan D. Chaparro, MD, MS, FAAP

Jeremy J. Michel, MD, MHS, FAAP

David W. Kimberlin, MD, FAAP – Red Book Editor

Ritu Banerjee, MD, PhD, FAAP – Red Book Associate Editor

Elizabeth D. Barnett MD, FAAP – Red Book Associate Editor

Ruth Lynfield, MD, FAAP – Red Book Associate Editor

Mark H. Sawyer, MD, FAAP – Red Book Associate Editor

Michelle Barton-Forbes, MD, Canadian Paediatric Society

Cristina V. Cardemil, MD, MPH, FAAP, National Institutes of Health

Karen M. Farizo, MD, US Food and Drug Administration

Lisa M. Kafer, MD, FAAP, Committee on Practice Ambulatory Medicine

Denee Moore, MD, FAAFP, American Academy of Family Physicians

Chinedu Okeke, MD, MPH-T, MPA, US Department of Health and Human Services

Chris Prestel, MD, Centers for Disease Control and Prevention

Manisha Patel, MD, MS, MBA, Centers for Disease Control and Prevention

Jeffrey R. Starke, MD, FAAP, American Thoracic Society

Jennifer Thompson, MD, American College of Obstetricians and Gynecologists

Juan Pablo Torres, MD, Sociedad Latinoamericana de Infectologia Pediatrica

Melinda Wharton, MD, MPH, Centers for Disease Control and Prevention

Charles R. Woods, Jr, MD, MS, FAAP, Pediatric Infectious Diseases Society

Gillian Gibbs, MPH

The Committee on Infectious Diseases gratefully acknowledges Kristina A. Bryant, MD, FAAP, and Annika M. Hofstetter, MD, PhD, MPH, FAAP, for their leadership in drafting the policy statement and technical report; Juan D. Chaparro, MD, MS, FAAP, and Jeremy J. Michel, MD, MHS, FAAP, for their significant contributions in providing input on the initial drafts on behalf of the AAP Partnership for Policy Initiative; and Jennifer Shaw for her editing assistance.

AAP

American Academy of Pediatrics

FDA

US Food and Drug Administration

IIV

inactivated (nonlive) influenza vaccine

IIV3

trivalent inactivated (nonlive) influenza vaccine

LAIV

live attenuated influenza vaccine

RIV

recombinant influenza vaccine